AzTrials
AzTrials

Anorexia NervosaANOSTOOLNCT03736642

Study of the Microbiological Profile of Stool in Patients With Anorexia Nervosa

An observational study of Anorexia Nervosa and Eating Disorder, run by Centre Hospitalier Universitaire de Saint Etienne at 1 site in France.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Anorexia nervosa is an eating disorder whose symptomatology induces a modification of the intestinal microbiota. To date, studies have shown variable profiles without linking them to metabolic and neuropsychological energy phenotyping. This intestinal dysbiosis could be involved in the maintenance of the disorders. Read more about this study

Who is it for?
Ages 18 to 30 years, women onlyHealthy volunteers can take part
Conditions the study is for
Anorexia Nervosa, Eating Disorder
What is being tested?
blood sampling, stool sampling and urine sampling
How many people
0 participants
Where
1 siteFrance
Study dates
15 May 2019to 15 May 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 30 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Study population: * anorexia nervosa with and without hunger * constitutional leanness * control subjects

Who may be able to join

  • Patient affiliated or entitled to a social security scheme
  • Patient who received informed information about the study
  • Patient does not object to participating in the study
  • BMI between 13 and 17.5 kg/m2
  • Diagnostic and Statistical Manual of Mental Disorders IV restrictive anorexia nervosa diagnostic criteria
  • Evolution of the troubles since less than 1 year.
Show all 27Show fewer
  • with feeling of hunger: "hunger" = total score on the 24-hour hunger scale > 15 and presence of the three prandial peaks (score = 3)
  • having lost the feeling of hunger: "not hungry" = total score on the 24-hour hunger scale ≤ 5 and absence of the three prandial peaks (score ≤ 2)
  • Inclusion criteria specific to constitutionally thin patients
  • BMI between 13 and 17.5 kg/m2
  • Stable weight for at least 3 months
  • No eating disorder
  • No markers of undernutrition
  • 20 kg/m2 ≤ BMI ≤ 25 kg/m2
  • Stable weight for at least 3 months
  • No eating disorder
  • No markers of undernutrition
  • Non-inclusion criteria for all subjects :
  • Antibiotic treatment during the 2 months preceding the sampling.
  • History of immune system/autoimmune disease: Immune deficiency, Crohn's disease, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, psoriasis, Behçet's disease, celiac disease, type I diabetes.
  • History of metabolic pathology: intestinal malabsorptive disease
  • Medical or surgical history deemed by the investigator to be incompatible with this study.
  • Severe progressive condition other
  • Pregnant woman
  • Majors under guardianship or subjects deprived of their liberty by judicial or administrative decision
  • Ongoing psychotropic treatment
  • Progressive diarrhea (Bristol Type V and VI)

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

France1 site
  • Chu Saint-Etienne

    Saint-Etienne, 42055

Other trials in France

About this study

Anorexia nervosa is an eating disorder whose symptomatology induces a modification of the intestinal microbiota. To date, studies have shown variable profiles without linking them to metabolic and neuropsychological energy phenotyping. This intestinal dysbiosis could be involved in the maintenance of the disorders. Bidirectional communication channels exist between the microbiota, the intestine and the brain. Anomalies in these pathways could explain the impact of the microbiota on the pathophysiology of anorexia nervosa. Therapeutic interventions would then be possible to restore the microbiota in anorexia nervosa and influence the treatment of this disease. This study aims to explore the hypothesis of disruption of the microbiota-intestinal-brain axis transversely and measuring the intestinal microbiota, urinary metabolome, biological factors nutritional, immunological and physiological plasma plasma of the intestine, and finally, the psychological dimensions characteristic of anorexia nervosa.

Being tested
blood sampling, stool sampling, urine sampling, neuropsychological tests
Keywords
stool, constitutional thinness
Medical subject headings
Anorexia Nervosa, Feeding and Eating Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • blood samplingBiological

    12 ml sample

  • stool samplingOther

    20 g sample

  • urine samplingOther

    18 ml sample

  • neuropsychological testsDiagnostic test

    • Go-nogo
    • flexibility
    • food stroop
    • implicit and explicit evaluation
    • Child Depression Inventory
    • Hamilton Depression Rating Scale
Study groups in NCT03736642
Study groupRoleWhat they receive
restrictive anorexia nervosa with hungerNot described
Receives: Biological: blood sampling; Other: stool sampling; Other: urine sampling; Diagnostic Test: neuropsychological tests
restrictive anorexia nervosa without hungerNot described
Receives: Biological: blood sampling; Other: stool sampling; Other: urine sampling; Diagnostic Test: neuropsychological tests
constitutional thinnessNot described
Receives: Biological: blood sampling; Other: stool sampling; Other: urine sampling; Diagnostic Test: neuropsychological tests
control subjects without eating disordersNot described
Receives: Biological: blood sampling; Other: stool sampling; Other: urine sampling; Diagnostic Test: neuropsychological tests

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. determination of bacterial microbiological profile by 16s sequencing of stool samples

    Measured: at inclusion

Secondary outcomes (10)
  1. Determination of the metabolomic profile

    evaluated by mass spectrometry (MS/MS) of urine

    Measured: at inclusion

  2. Neurocognitive evaluation

    evaluated with questionnaire go-nogo

    Measured: at 2 months

  3. Neurocognitive evaluation

    evaluated with questionnaire of flexibility

    Measured: at 2 months

  4. Neurocognitive evaluation

    evaluated with questionnaire : food troop

    Measured: at 2 months

  5. Neurocognitive evaluation

    evaluated with questionnaires : implicit and explicit evaluation.

    Measured: at 2 months

  6. Psychometric scaling for thymic evaluation

    evaluated with questionnaire : Child Depression Inventory

    Measured: at 2 months

  7. Psychometric scaling for thymic evaluation

    evaluated with questionnaire : Hamilton Depression Rating Scale

    Measured: at 2 months

  8. Determination of the plasma profile of intestinal physiology markers and immunological markers

    Intestinal permeability markers: ASCA, antiglycan, anti GP2 IgG/IgA, calprotectin

    Measured: at inclusion

  9. Determination of the plasma profile of intestinal physiology markers and immunological markers

    immunoglobulin repertoire: A and M, inflammatory molecules: C-reactive protein

    Measured: at inclusion

  10. Determination of the plasma profile of intestinal physiology markers and immunological markers

    circulating interleukins of the Th17 profile: IL17, IL23, IL6, IL1β, IL 22, IL21, IL33, IL31, TNFα, IFNγ, IL9, IL10, IL4.

    Measured: at inclusion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Nov 2018
  2. Study start15 May 2019
  3. Primary completion15 May 2019
  4. Study completion15 May 2019

Why it stopped: never started

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03736642
Sponsor's protocol ID
18CH109
Other IDs
2018-A01731-54
Acronym
ANOSTOOL
Status last verified
Jul 2020
First submitted
2 Nov 2018
Last updated
30 Jul 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Anorexia Nervosa and Eating Disorder, run by Centre Hospitalier Universitaire de Saint Etienne at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 27 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 30 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

determination of bacterial microbiological profile by 16s sequencing of stool samples (time frame: at inclusion). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in